Keywords
Hepatitis C, Chronic ×
Eligibility Determination ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

98 Search results.

Eligibility Genotype 1 Chronic Hepatitis C NCT01241760

- 6/9/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection; ODM derived from: https://clinicaltrials.gov/show/NCT01241760

Eligibility Genotype 1 Chronic Hepatitis C NCT01498068

- 6/9/20 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT01498068

Eligibility Hepatitis C, Chronic NCT01554189

- 5/21/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002); ODM derived from: https://clinicaltrials.gov/show/NCT01554189

Eligibility Genotype 4 Chronic Hepatitis C Infection NCT01653236

- 12/20/19 - 1 form, 3 itemgroups, 16 items, 1 language
Itemgroups: Criteria, Inclusion Criteria, Exclusion Criteria
Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection; ODM derived from: https://clinicaltrials.gov/show/NCT01653236

Eligibility Early Chronic Hepatitis C NCT01743521

- 12/3/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C); ODM derived from: https://clinicaltrials.gov/show/NCT01743521

Herpes Simplex Type 1 Suppression in Hepatitis C NCT01580995 - Eligibility Criteria

- 5/14/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Herpes Simplex Type 1 Suppression in Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT01580995 Brief Summary: The purpose of this study is to examine the effects of valacyclovir in patients who have chronic hepatitis C, antibodies to herpes simplex type 1 infection but do not have antibodies to herpes simplex type 2 infection. Herpes simplex type 1 infection commonly causes cold sores or fever blisters, also known as herpes labialis, but most persons do not have any symptoms at all. Valacyclovir is a medication which is approved by the Food and Drug administration to treat herpes labialis. Valacyclovir has not been approved to treat chronic hepatitis C infection. The study will take 16 weeks. Participants will be assigned to take either the study drug, valacyclovir, or a sugar pill that looks exactly like valacyclovir. The researchers and patients will not know which medication they are receiving. Study visits will occur every two weeks and will take approximately 30-45 minutes. All study visits will occur at the G.V. Sonny Montgomery VA Medical Center in Jackson, Mississippi.

RO5024048 in Combination with Pegasys and Copegus in Chronic Hep C NCT01057667 - Eligibility Criteria

- 4/15/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4; ODM derived from: https://clinicaltrials.gov/show/NCT01057667

Eligibility Hepatitis C, Chronic NCT02421211

- 4/12/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection; ODM derived from: https://clinicaltrials.gov/show/NCT02421211

Eligibility Hepatitis C, Chronic NCT02262728

- 4/12/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease; ODM derived from: https://clinicaltrials.gov/show/NCT02262728

Eligibility Hepatitis C, Chronic NCT02461745

- 4/12/19 - 1 form, 1 itemgroup, 19 items, 1 language
Itemgroup: Criteria
Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs; ODM derived from: https://clinicaltrials.gov/show/NCT02461745

Eligibility Hepatitis C, Chronic NCT02027116

- 4/11/19 - 1 form, 2 itemgroups, 31 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection; ODM derived from: https://clinicaltrials.gov/show/NCT02027116

Eligibility Chronic Hepatitis C Virus NCT02105467

- 2/25/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060); ODM derived from: https://clinicaltrials.gov/show/NCT02105467